Nurix therapeutics announces presentations at the 67th american society of hematology (ash) annual meeting

San francisco, nov. 03, 2025 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the nx-5948-301 phase 1a/1b clinical trial have been selected for presentation at the 67th american society of hematology (ash) annual meeting and exposition, taking place december 6 – 9, 2025, in orlando, florida. the data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (cll) and a poster presentation with updated results in patients with waldenstrÖm macroglobulinemia.
ASH Ratings Summary
ASH Quant Ranking